Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
Am J Cardiol. 2022 May 15;171:65-68. doi: 10.1016/j.amjcard.2022.01.046. Epub 2022 Mar 12.
Spontaneous coronary artery dissection (SCAD) is a relatively newly diagnosed area, and evidence-based medicine (EBM) standards are emerging and currently include an aspirin, β blocker, clopidogrel, angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker for patients with hypertension, vascular abnormality imaging, and cardiac rehabilitation. Because SCAD is an uncommon condition, many providers are unfamiliar with EBM treatment standards which could affect the implementation of recommended treatment. This study documented the frequency of failure to meet EBM SCAD treatment standards and factors contributing to conformance failure. Patients who presented to a tertiary referral hospital from January 1, 2005, to July 6, 2020, were included. The electronic medical record was reviewed for EBM treatment. Patients who did not meet the criteria of EBM were contacted by phone for a phone interview. The study period included 118 patients with SCAD, 3 of whom (2.5%) died and were not eligible for this study. In the final cohort of 115 patients, the average age was 55 years, female gender (97%) and EBM standards were met in 30%. Of patients who participated in the phone interview, 38 (33%) reported frustration with SCAD misdiagnosis (39%), inadequate mental health resources (37%), and communication failure regarding the need for cardiologist follow-up (26%). Cardiac rehabilitation use was impacted by location, time of day, availability, and cost. The most common medication-limiting factor for β-blocker usage was fatigue (15%). Most (59%) patients did not undergo fibromuscular dysplasia imaging. In conclusion, in this 15-year SCAD study from a single tertiary care hospital SCAD registry, only 30% met the current EBM for SCAD. Unique solutions that are both patient-informed and evidence-driven are needed to achieve the best clinical outcomes.
自发性冠状动脉夹层 (SCAD) 是一个相对较新的诊断领域,循证医学 (EBM) 标准正在出现,目前包括阿司匹林、β受体阻滞剂、氯吡格雷、血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂用于高血压患者、血管异常成像和心脏康复。由于 SCAD 是一种罕见的疾病,许多提供者不熟悉 EBM 治疗标准,这可能会影响推荐治疗的实施。本研究记录了不符合 EBM SCAD 治疗标准的频率以及导致一致性失败的因素。纳入了 2005 年 1 月 1 日至 2020 年 7 月 6 日期间在三级转诊医院就诊的患者。对电子病历进行了 EBM 治疗审查。未符合 EBM 标准的患者通过电话联系进行电话访谈。研究期间包括 118 例 SCAD 患者,其中 3 例(2.5%)死亡,不符合本研究条件。在最终的 115 例患者队列中,平均年龄为 55 岁,女性(97%),符合 EBM 标准的患者占 30%。参加电话访谈的患者中,有 38 人(33%)报告对 SCAD 误诊感到沮丧(39%)、精神卫生资源不足(37%)以及关于需要心脏病专家随访的沟通失败(26%)。心脏康复的使用受到位置、时间、可用性和成本的影响。β受体阻滞剂使用的最常见药物限制因素是疲劳(15%)。大多数(59%)患者未进行纤维肌性发育不良成像。总之,在这项来自单一三级保健医院 SCAD 登记处的 15 年 SCAD 研究中,只有 30%符合当前 SCAD 的 EBM。需要既考虑患者又基于证据的独特解决方案,以实现最佳的临床结果。